Earlier this month, Merck and Daiichi Sankyo announced that ifinatamab deruxtecan was granted Breakthrough Therapy Designation by the U.S. FDA for treating adult patients with extensive-stage small ...

Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...

Rahway: Merck and Daiichi Sankyo have announced that Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy ...

Developed by Daiichi Sankyo and Merck, it treats patients with Pretreated Extensive-Stage Small Cell Lung Cancer.

Ifinatamab deruxtecan has been granted Breakthrough Therapy Designation by the FDA for the treatment of adult patients with extensive-stage small ...

The treatment is one of three antibody-drug conjugates (ADCs) included in Merck's up to $22-billion joint development and commercialization deal with Daiichi Sankyo, signed last year.

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival ...

Sept 17 (Reuters) - Daiichi Sankyo (4568.T) and Merck (MRK.N) said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung ...

Merck, Daiichi Sankyo Say Biologics License Application Withdrawn For Patritumab Deruxtecan May 29, 2025 — 08:06 am EDT Written by RTTNews.com for RTTNews -> ...

On Oct. 19, narrow-moat Daiichi Sankyo announced an out-licensing deal with Merck for three of Daiichi’s antibody-drug conjugate candidates. The total up-front payments are $5.5 billion, up to ...

AbbVie ABBV is known for its strong immunology franchise comprising blockbuster drugs like Skyrizi, Rinvoq and Humira.

(RTTNews) - Daiichi Sankyo Company Limited (DSKYF.PK) and Merck & Co Inc. (MRK) Tuesday said they have expanded their development and commercialization agreement to include Merck's MK-6070, an ...